Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck

Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.

Osteoporosis

Amgen Inc. and UCB Group have appeared to lock in their head start in the race to get new osteoporosis biologics market, with the July 21 announcement that they had submitted the biologics license application (BLA) submission to the US FDA for their investigational monoclonal antibody romosozumab.

The drug works by binding and inhibiting sclerostin (a protein naturally occurring in the bone) thereby increasing bone formation and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip